Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study. [PDF]
This paper presents the results of an observational and retrospective study on the therapeutic effects of Jusvinza, an immunomodulatory peptide with anti-inflammatory properties for critically ill COVID-19 patients.
Rafael Venegas-Rodríguez +12 more
doaj +6 more sources
Proteomic Profile Regulated by the Immunomodulatory Jusvinza Drug in Neutrophils Isolated from Rheumatoid Arthritis Patients [PDF]
Jusvinza is an immunomodulatory drug composed of an altered peptide ligand (APL) designed from a novel CD4+ T cell epitope of human heat shock protein 60 (HSP60), an autoantigen involved in the pathogenesis of rheumatoid arthritis (RA).
Mabel Hernández-Cedeño +10 more
doaj +8 more sources
Anti-Inflammatory Activity of CIGB-258 against Acute Toxicity of Carboxymethyllysine in Paralyzed Zebrafish via Enhancement of High-Density Lipoproteins Stability and Functionality. [PDF]
Background: Hyperinflammation is frequently associated with the chronic pain of autoimmune disease and the acute death of coronavirus disease (COVID-19) via a severe cytokine cascade.
Cho KH, Kim JE, Nam HS, Kang DJ, Na HJ.
europepmc +3 more sources
The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19 [PDF]
Introduction: Infection with SARS-CoV-2 induces a prothrombotic state in patients, by the combination of hyperinflammatory response and hypoxia. In Cuba, the drug called Jusvinza, based on an immunomodulatory peptide, is used for the treatment of ...
Rafael Venegas Rodríguez +13 more
doaj +5 more sources
Características clínicas, radiológicas y laboratoriales de pacientes con COVID-19 tratados con Jusvinza [PDF]
Introducción: El tratamiento con anticuerpos monoclonales en la infección por SARS-CoV-2 es controversial, algunos protocolos lo recomiendan para pacientes con enfermedad grave o en estado crítico.
Yanet Damarys Acosta Perdomo +3 more
doaj +6 more sources
Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 [PDF]
Foundation: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of
Sandra Caridad Laurencio Vallina +4 more
doaj +3 more sources
Tratamiento con antiinflamatorios en paciente de alto riesgo Covid 19, evolución de la enfermedad, presentación de caso clínico [PDF]
On March 11, 2020, covid 19 was considered a pandemic by the WHO, that same day the first case in Cuba is confirmed from an Italian tourist. In the province of Las Tunas during the month of August there is a deliberate increase in the number of cases ...
Cruz Fernández, Elider +2 more
core +5 more sources
Diabetes, hiperglucemia y evolución de pacientes con la COVID-19 [PDF]
Introducción: La diabetes mellitus e hiperglucemia, en pacientes con la COVID-19, predisponen a mayor gravedad de la enfermedad y peores resultados a corto plazo.
Rubén González Tabares +4 more
doaj +4 more sources
Péptido inmumodulador CIGB-258 para el tratamiento de pacientes graves y críticos con la COVID-19 [PDF]
Introducción: El CIGB-258 es un péptido inmunomodulador con propiedades antiinflamatorias. Objetivos: Establecer la frecuencia de dosis y el tiempo de tratamiento con el péptido CIGB-258, para pacientes críticos con la COVID-19.
Rafael Venegas Rodríguez +14 more
doaj +4 more sources
CIGB-258, a Potential Novel Approach to Treat Sepsis-like Hyperinflammation, Reduces Gastrointestinal Hemorrhage in Zebrafish Exposed to Carboxymethyllysine and Ethanol [PDF]
Objective: CIGB-258 is a 3 KDa altered peptide ligand recognized for its anti-inflammatory activity. Herein, the effect of CIGB-258 was assessed against carboxymethyllysine (CML) and ethanol (Et-OH)-induced sepsis-like events in zebrafish (Danio rerio ...
Kyung-Hyun Cho +5 more
doaj +2 more sources

